Articles related to HEREDITARY ANGIOEDEMA (HAE)

In a phase 3 trial, oral sebetralstat demonstrated a median time to beginning of symptom relief of 1.61 hours for the 300 mg dose and 1.79 hours for the 600 mg dose, compared to 6.72 hours for placebo in hereditary angioedema attacks.

Can you differentiate between bradykinin-mediated angioedema and the more common histamine-mediated angioedema? How significant is a delayed diagnosis? Do you favor on-demand or preventative therapy? What is the recommended therapy? Access to specialist care and effective treatment in the past 10 years has improved the quality of life and reduced the mortality rate in patients with hereditary angioedema. This wide-ranging report from the British Journal of Hospital Medicine covers emerging treatments and outlines where we’ve been, where we are, and where we’re going in hereditary angioedema (HAE) care.

Often undiagnosed due to its unspecific symptoms, hereditary angioedema (HAE) is a tricky condition that causes many patients unnecessary suffering with unnecessary surgeries and invasive diagnostic/therapeutic interventions. Read on to educate yourself on some of the alarming numbers on the orphan disease.   

Findings: Primary outcomes included AMI, HF, stroke, and CVEs; 51 secondary and safety outcomes included angioedema, cough, syncope, and electrolyte abnormalities. ACE inhibitors were associated with a significantly increased risk of four secondary and safety outcomes compared with ARBs.Design: Multinational cohort study; Patients: ~2.3M ACE, ~674K ARB